Search results
Results From The WOW.Com Content Network
ICE in the context of chemotherapy is an acronym for one of the chemotherapy regimens, used in salvage treatment of relapsed or refractory non-Hodgkin's lymphoma and Hodgkin lymphoma. In case of CD20-positive B cell lymphoid malignancies the ICE regimen is often combined today with rituximab. This regimen is then called ICE-R or R-ICE or RICE.
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
A large number of hierarchies of evidence have been proposed. Similar protocols for evaluation of research quality are still in development. So far, the available protocols pay relatively little attention to whether outcome research is relevant to efficacy (the outcome of a treatment performed under ideal conditions) or to effectiveness (the outcome of the treatment performed under ordinary ...
1900 – Swedish Dr. Stenbeck cures a skin cancer with small doses of radiation [4]; 1920s – Dr. William B. Coley's immunotherapy treatment, regressed tumors in hundreds of cases, the success of Coley's Toxins attracted heavy resistance from his rival and supervisor, Dr. James Ewing, who was an ardent supporter of radiation therapy for cancer.
"7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as first-line induction therapy (to induce remission) in acute myelogenous leukemia, [1] [2] excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or arsenic trioxide and requires less chemotherapy (if requires it at all, which is not always ...
Cancer Treatment Centers of America was the subject of a Federal Trade Commission (FTC) complaint in 1993 alleging that CTCA made false claims regarding the success rates of certain cancer treatments in marketing and promotional materials. Among other unsubstantiated claims, CTCA advertised that it was able to treat certain forms of cancer ...
The American National Comprehensive Cancer Network's official guidelines list TTFields as an option for the treatment of recurrent glioblastoma, but note substantial disagreement among the members of the expert panel making this recommendation. [2] High-quality evidence for the efficacy of TTFields in oncology is limited.
The main product of the CONSORT Group is the CONSORT Statement, [1] which is an evidence-based, minimum set of recommendations for reporting randomized trials.It offers a standard way for authors to prepare reports of trial findings, facilitating their complete and transparent reporting, reducing the influence of bias on their results, and aiding their critical appraisal and interpretation.